Markel Group Inc. Has $32.98 Million Stock Position in Thermo Fisher Scientific Inc. $TMO

Markel Group Inc. raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 67,100 shares of the medical research company’s stock after buying an additional 4,300 shares during the quarter. Markel Group Inc.’s holdings in Thermo Fisher Scientific were worth $32,982,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of TMO. Howard Capital Management Inc. raised its stake in Thermo Fisher Scientific by 0.5% during the 4th quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company’s stock valued at $1,791,000 after purchasing an additional 16 shares during the last quarter. Petros Family Wealth LLC grew its position in Thermo Fisher Scientific by 3.9% in the 4th quarter. Petros Family Wealth LLC now owns 456 shares of the medical research company’s stock worth $264,000 after purchasing an additional 17 shares during the last quarter. Salomon & Ludwin LLC raised its position in shares of Thermo Fisher Scientific by 1.6% during the fourth quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company’s stock valued at $669,000 after buying an additional 17 shares during the last quarter. Pallas Capital Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 1.5% in the fourth quarter. Pallas Capital Advisors LLC now owns 1,256 shares of the medical research company’s stock valued at $728,000 after buying an additional 18 shares during the period. Finally, Red Door Wealth Management LLC grew its position in Thermo Fisher Scientific by 0.8% during the fourth quarter. Red Door Wealth Management LLC now owns 2,156 shares of the medical research company’s stock worth $1,250,000 after buying an additional 18 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO traded up $2.01 during midday trading on Friday, reaching $526.72. 1,233,008 shares of the company traded hands, compared to its average volume of 1,993,707. The stock’s 50-day simple moving average is $478.23 and its 200-day simple moving average is $516.44. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. Thermo Fisher Scientific Inc. has a 12 month low of $403.36 and a 12 month high of $643.99. The firm has a market cap of $195.74 billion, a PE ratio of 28.96, a PEG ratio of 2.33 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period last year, the firm posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is 10.34%.

Insiders Place Their Bets

In related news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Wolfe Research initiated coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price target for the company. Barclays cut their target price on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research note on Tuesday, April 14th. HSBC downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their price target for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Piper Sandler initiated coverage on shares of Thermo Fisher Scientific in a report on Thursday, June 11th. They set a “neutral” rating and a $510.00 price objective for the company. Finally, DZ Bank started coverage on shares of Thermo Fisher Scientific in a research note on Friday, March 27th. They issued a “buy” rating and a $610.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $602.14.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.